Business
Why has the Telix (ASX:TXL) share price shot up 5% today?
The Telix Pharmaceuticals Ltd (ASX: TLX) share price is racing higher after the company announced a new phase in its drug trials. The company confirmed it will proceed with the Phase III of ProstACT study for its TLX591 drug, a prostate cancer treatment.
The company also advised this morning that it has entered into a commercialisation and partnership agreement with DuChemBio, a leading South Korean radiopharmaceutical company.
At the time of writing, the Telix share price has surged up 5% to $4.20.
About the Phase III testing
Telix recently met with the United States Food and Drug Administration (FDA) to discuss the company’s planned Phase III ProstACT trial for TLX591. Today’s announcement is the result of that meeting.
The…
-
Noosa News7 hours agoThe grey backstreet of Brisbane’s Fortitude Valley where Arnie the missing dog was found dead in his owner Nathan McKeown’s black ute
-
General18 hours agoMildura man given 28 years to pay $73,000 in unpaid fines and tolls
-
General21 hours agoAustralia’s race to rewire the country amid a global transmission boom is not unique
-
Business20 hours ago3 ASX 200 shares that could be top buys for growth